Submit Manuscript  

Article Details


Feasibility of Targeting Glioblastoma Stem Cells: From Concept to Clinical Trials

[ Vol. 19 , Issue. 32 ]

Author(s):

Vadim V. Tarasov, Andrey A. Svistunov, Vladimir N. Chubarev, Tamara A. Zatsepilova, Nina G. Preferanskaya, Olga I. Stepanova, Alexander V. Sokolov, Samira A. Dostdar, Nina N. Minyaeva, Margarita E. Neganova, Sergey G. Klochkov, Liudmila M. Mikhaleva, Siva G. Somasundaram, Cecil E. Kirkland and Gjumrakch Aliev*   Pages 2974 - 2984 ( 11 )

Abstract:


Objective: Glioblastoma is a highly aggressive and invasive brain and Central Nervous System (CNS) tumor. Current treatment options do not prolong overall survival significantly because the disease is highly prone to relapse. Therefore, research to find new therapies is of paramount importance. It has been discovered that glioblastomas contain a population of cells with stem-like properties and that these cells are may be responsible for tumor recurrence.

Methods: A review of relevant papers and clinical trials in the field was conducted. A PubMed search with related keywords was used to gather the data. For example, “glioblastoma stem cells AND WNT signaling” is an example used to find information on clinical trials using the database ClinicalTrials.gov.

Results: Cancer stem cell research has several fundamental issues and uncertainties that should be taken into consideration. Theoretically, a number of treatment options that target glioblastoma stem cells are available for patients. However, only a few of them have obtained promising results in clinical trials. Several strategies are still under investigation.

Conclusion: The majority of treatments to target cancer stem cells have failed during clinical trials. Taking into account a number of biases in the field and the number of unsuccessful investigations, the application of the cancer stem cells concept is questionable in clinical settings, at least with respect to glioblastoma.

Keywords:

Glioblastoma, Cancer stem cells, Brain tumor, Stem cell self-renewal, Molecular targeted therapy, Vaccine therapy, CAR T-cell therapy.

Affiliation:

Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow 101000, Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow 117418, Department of Biological Sciences, Salem University, Salem, WV, Department of Biological Sciences, Salem University, Salem, WV, Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991

Graphical Abstract:



Read Full-Text article